Literature DB >> 17504685

[Seroprevalence of viral hepatitis in a representative general population of an urban public health area in Castilla y León (Spain)].

Raúl López-Izquierdo1, M Antonia Udaondo, Pilar Zarzosa, Elpidio García-Ramón, Sonsoles Garcinuño, Miguel Angel Bratos, Antonio Orduña, Antonio Rodríguez-Torres, Ana Almaraz.   

Abstract

INTRODUCTION: Viral hepatitis is a major social, health and economic problem worldwide, requiring strict epidemiological control.
METHODS: This study presents the viral hepatitis seroprevalence in a representative sample from an urban health care area in Valladolid (Spain).
RESULTS: Antibody prevalence was as follows: anti-HAV 52%; anti-HBc, 8.2%; anti-HCV, 1.1%; anti-HEV, 0.8%; and anti-HGV 5.8%. Prevalence of anti-HAV, anti-HBc and anti-HGV increased significantly with age (P < 0.005 in all cases). In individuals younger than 20, prevalence of anti-HAV was 3.8%, anti-HBc < 0.28% and anti-HGV 1.3%. In the 20-39 year-old group, seroprevalence against HAV was associated with low educational levels (P = 0.009) and with birth in other provinces (P = 0.016). Anti-HBc seroprevalence was mainly associated with three factors: prior hospitalization before 1990 (P = 0.002; OR 3.32 [1.48-7.42]); compulsory military service before 1990 (P < 0.0001; OR 37.33 [3.68-378.03]); and acupuncture treatments (P = 0.018; OR 57.75 [26.17-127.42]). Seroprevalence against HGV was associated with hospitalizations before 1990 (P = 0.019; OR = 2.969 [1.154-7.639]). Seropositive status to HCV revealed a transfusion history (2 cases), hospitalization (1 case) or drug addiction (1 case). Only one case among those seropositive to HEV had a history of a prior trip to a HEV-endemic area.
CONCLUSIONS: Our study shows that the seroprevalences of viral hepatitis in a representative sample of urban population of Castille and Leon are similar to the seroprevalences observed in the rest of Spain and other developed countries, lower than the ones observed in the studies performed in Spain in the last 20 years due to the measures of prophylaxis that were taken.

Entities:  

Mesh:

Year:  2007        PMID: 17504685     DOI: 10.1157/13102267

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  3 in total

Review 1.  Hepatitis E Virus in Industrialized Countries: The Silent Threat.

Authors:  Pilar Clemente-Casares; Carlota Ramos-Romero; Eugenio Ramirez-Gonzalez; Antonio Mas
Journal:  Biomed Res Int       Date:  2016-12-14       Impact factor: 3.411

2.  Hepatitis C hospitalizations in Spain, 2004-2013: a retrospective epidemiological study.

Authors:  R Boix; R Cano; P Gallego; F Vallejo; R Fernández-Cuenca; I Noguer; A Larrauri
Journal:  BMC Health Serv Res       Date:  2017-07-05       Impact factor: 2.655

Review 3.  Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review.

Authors:  S H I Hofstraat; A M Falla; E F Duffell; S J M Hahné; A J Amato-Gauci; I K Veldhuijzen; L Tavoschi
Journal:  Epidemiol Infect       Date:  2017-09-11       Impact factor: 2.451

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.